# Trade Mark Journal No.2025/050 12 December 2025

## UK00004270847 29 September 2025 (5)

BHYLOR

International priority date claimed: 31 March 2025 (United States of America) (99112415)

Class 5
  Pharmaceutical preparations for the prevention and treatment of hypertension, sleep apnea, chronic kidney disease, heart failure, primary aldosteronism, myocardial infarction, coronary artery disease, blood vessel wall thickening, renal fibrosis, nephropathy, and vascular dementia.

Mineralys Therapeutics, Inc.

Representative: HGF Limited